Fancy a splash in the gene pool?

The Motley Fool started as a newsletter and has become one of the most popular personal finance websites. Anyone who follows its philosophy is called a 'Foolish investor'

When looking for companies that are really breaking the mould, introducing new products and services in emerging markets, it is sometimes hard to see beyond the burgeoning internet.

There should be some great winners in the internet business and, as we keep saying at the Motley Fool, in the future all companies will have to be internet companies to some degree. But at the moment it is very difficult to separate the wheat from the chaff.

So where else can we look? The biotechnology sector is one that has attracted a number of followers over the last few years. But the failures at British Biotech earlier this year, when the clinical effectiveness of some of its trial therapies was overstated, caused more than a few investors to go to bed early and nurse their burnt fingers.

So we need to be careful and always remember the Foolish maxim to never invest in something we don't understand. To many, that might appear to exclude the biotechnology sector altogether.

At Fool HQ, where we count an ex-GP and a biochemistry graduate among our number, we struggle with some bio- technology companies, whose futures are usually far too uncertain for us in any case.

But the power of the Fool's online community lends us great strength, and one of our message board regulars, who is in the business, has been at hand to help our understanding of technical issues. And so, we have been dipping our Foolish toes into the mysterious waters of pharmacogenomics. Now that's a big word, so what does it mean? Well, it really just boils down to the following:

1 Our genes control everything that happens in our bodies.

2 Probably all drugs act by affecting genes in some way.

3 Studying the pattern of gene activation in an individual can potentially tell us things about their health, the state of their disease, the effect of drugs taken so far and the likelihood of future drugs being effective.

4 Pharmacogenomics is the study of the effect of drugs on gene activation.

Now we understand that, let's get back to financial caution for a moment. In the eyes of Fool HQ, most biotechnology companies can be likened to miners in the great gold rushes. Only a very few lucky ones will strike the mother lode. But meanwhile the guy in the chuck- wagon, or the bloke selling the blue jeans, makes a packet. Providing the tools for the job and letting the other suckers take the risk is nearly always a profitable strategy and an American company, Affymetrix, looks at first sight like it might fit that bill. But what does it do?

With 100,000 genes to sift through, examining individual genes within the human body is time-consuming to say the least. However, the gene chip microarray technology to which Affymetrix holds patents allows researchers to examine many thousands of genes at the same time. Commercial sales of "gene chips" began in 1996, and as far as we can tell, the company has no direct competitors.

Affymetrix is clearly the first mover and top dog in its market. It has support from a number of very important customers, and probably has a sustainable advantage because of its patented technology.

But we are undecided about investing in Affymetrix and will be doing a lot more hard thinking before we make a decision. Our chief concern is the size and importance of the company's potential market. Its particular technology is best suited to the world of clinical research, but the diagnostics market, in which similar but simpler and cheaper technologies will be needed, may well eclipse the research market in commercial importance.

We will be returning to this subject. For now, though, please remember that our cogitations here do not constitute tips. Never blindly rush in and buy anything we talk about. Fools always do their own research and make their own decisions.



Recently I discovered shares traded off-exchange (see Why are these not better publicised in the newspapers and online?

PW, London

The Fool replies: Ofex does not constitute a "proper" stock exchange, which means that it has no market makers to buy and sell shares. If you wanted to buy something, for example, your broker would have to find another individual wanting to sell the same thing at a mutually agreeable price. It can thus be difficult to buy or sell when you want to.

If we publish your question, you'll win a copy of 'The Motley Fool UK Investment Guide'. Email or post to Motley Fool, 79 Baker Street, London W1M 1AJ.


The first five correct answers out of the hat win a copy of 'The Motley Fool UK Investment Guide'.

Which recently downtrodden private monopoly saw its share price rise this week after announcing increased estimates of its planned infrastructure spending?

n Answers by email to: or by post to: Motley Fool, 79 Baker Street, London W1M 1AJ.

n Last week's answer: Kirch Pay TV

Start your day with The Independent, sign up for daily news emails
Arts and Entertainment
tvThe C-Word, TV review
Arts and Entertainment
The Ridiculous Six has been produced by Adam Sandler, who also stars in it
filmNew controversy after nine Native American actors walked off set
Danny Jones was in the Wales squad for the 2013 World Cup
rugby leagueKeighley Cougars half-back was taken off after just four minutes
Life and Style
The original ZX Spectrum was simple to plug into your TV and get playing on
techThirty years on, the ZX Spectrum is back, after a fashion
Tiger Woods and Lindsey Vonn are breaking up after nearly three years together
peopleFormer couple announce separation in posts on their websites
Life and Style
Google celebrates Bartolomeo Cristofori's 360th birthday
techGoogle Doodle to the rescue
Arts and Entertainment
Haunted looks: Matthew Macfadyen and Timothy Spall star in ‘The Enfield Haunting’
tvThe Enfield Haunting, TV review
The Mattehorn stands reflected in Leisee lake near Sunnegga station on June 30, 2013 near Zermatt, Switzerland
ebooksA celebration of British elections
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Claims Administrator

£16000 - £18500 per annum: Recruitment Genius: This is an excellent opportunit...

Recruitment Genius: Senior SEO Executive

£24000 - £28000 per annum: Recruitment Genius: A Senior SEO Executive is requi...

Recruitment Genius: Online Customer Service Administrator

£16000 - £18000 per annum: Recruitment Genius: An Online customer Service Admi...

Recruitment Genius: Digital Marketing Executive

£18000 - £22000 per annum: Recruitment Genius: This global, industry leading, ...

Day In a Page

Fishing for votes with Nigel Farage: The Ukip leader shows how he can work an audience as he casts his line to the disaffected of Grimsby

Fishing is on Nigel Farage's mind

Ukip leader casts a line to the disaffected
Who is bombing whom in the Middle East? It's amazing they don't all hit each other

Who is bombing whom in the Middle East?

Robert Fisk untangles the countries and factions
China's influence on fashion: At the top of the game both creatively and commercially

China's influence on fashion

At the top of the game both creatively and commercially
Lord O’Donnell: Former cabinet secretary on the election and life away from the levers of power

The man known as GOD has a reputation for getting the job done

Lord O'Donnell's three principles of rule
Rainbow shades: It's all bright on the night

Rainbow shades

It's all bright on the night
'It was first time I had ever tasted chocolate. I kept a piece, and when Amsterdam was liberated, I gave it to the first Allied soldier I saw'

Bread from heaven

Dutch survivors thank RAF for World War II drop that saved millions
Britain will be 'run for the wealthy and powerful' if Tories retain power - Labour

How 'the Axe' helped Labour

UK will be 'run for the wealthy and powerful' if Tories retain power
Rare and exclusive video shows the horrific price paid by activists for challenging the rule of jihadist extremists in Syria

The price to be paid for challenging the rule of extremists

A revolution now 'consuming its own children'
Welcome to the world of Megagames

Welcome to the world of Megagames

300 players take part in Watch the Skies! board game in London
'Nymphomaniac' actress reveals what it was really like to star in one of the most explicit films ever

Charlotte Gainsbourg on 'Nymphomaniac'

Starring in one of the most explicit films ever
Robert Fisk in Abu Dhabi: The Emirates' out-of-sight migrant workers helping to build the dream projects of its rulers

Robert Fisk in Abu Dhabi

The Emirates' out-of-sight migrant workers helping to build the dream projects of its rulers
Vince Cable interview: Charging fees for employment tribunals was 'a very bad move'

Vince Cable exclusive interview

Charging fees for employment tribunals was 'a very bad move'
Iwan Rheon interview: Game of Thrones star returns to his Welsh roots to record debut album

Iwan Rheon is returning to his Welsh roots

Rheon is best known for his role as the Bastard of Bolton. It's gruelling playing a sadistic torturer, he tells Craig McLean, but it hasn't stopped him recording an album of Welsh psychedelia
Russell Brand's interview with Ed Miliband has got everyone talking about The Trews

Everyone is talking about The Trews

Russell Brand's 'true news' videos attract millions of viewers. But today's 'Milibrand' interview introduced his resolutely amateurish style to a whole new crowd
Morne Hardenberg interview: Cameraman for BBC's upcoming show Shark on filming the ocean's most dangerous predator

It's time for my close-up

Meet the man who films great whites for a living